Do you have Cold Agglutinin Disease (CAgD)?
We are looking for individuals who have been medically diagnosed with Primary CAgD to participate in a study to see whether a new investigational product can increase haemoglobin (Hgb) levels in order to eliminate the need for blood transfusions in the treatment of CAgD.
There is currently no cure for CAgD. Patients with severe CAgD can require numerous blood transfusions to manage their anaemia.
We are currently recruiting study participants who:
- Are 18 years of age or older.
- Have been medically diagnosed with Primary Cold Agglutinin Disease (CAgD).
The study will be split into two parts. For part A of the study, participants will need to attend 16 clinic visits over a 6-month period. For part B, participants will need to attend fortnightly clinic visits for up to 2 years.
You will be reimbursed for your time.
To see if you are eligible complete the questionnaire or call the Clinical Trials Centre on 07 5456 3797.
Cardinal Study: A Pivotal, Open-Label, Multicenter Study to Assess the Efficacy and Safety of BIVV009 in Patients with Primary Cold Agglutinin Disease who have a Recent History of Blood Transfusion.
Cadenza Study: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of BIVV009 in Patients with Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion.
Ethics approval – Bellberry Human Research Ethics Committee
If you experience difficulty completing the survey please email email@example.com